Overview
TRAP Study: Testosterone for Androgen Receptor Polymorphism
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-03-31
2025-03-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
To determine whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes (COCs) obtained after ovarian stimulation by more than 1.5 in patients with low ovarian reserve and androgen receptor polymorphism undergoing intracytoplasmic sperm injection (ICSI).Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Instituto Bernabeu
Criteria
Inclusion Criteria:- Patients with low ovarian reserve according to Bologna criteria: at least two of the
following three:
1. Age equal to or greater than 40 years.
2. Previous cycle with less than 4 oocytes retrieved.
3. Low ovarian reserve markers (antral follicle count <5-7; AMH <0.5-1.1 ng).
- Carriers of androgen receptor polymorphism: between 22 and 24 CAG repeats.
- Body Mass Index (BMI) less than 32.
- Indication for in vitro fertilization.
- Presence of both ovaries.
- Absence of ovarian cysts.
- Absence of endometriosis.
- Normal karyotype and fragile X study.
- Absence of severe male factor.
- Semen sample from ejaculate.
- Ability to comply with the study protocol.
- To have given written consent.
Exclusion Criteria:
- Non-compliance with instructions or non-formalization of informed consent.
- Concurrent participation in another study.